First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.

Liu Y, Zhang Y, Lin R, Chen X, Wang J, Yang M, Qu X, Li Y, Li J, Zhang W, Mao Y, Wang Z, Liu Z, Lei J, Xu Y, Jiang Y, Pan Z, Zhu L, Liu C, Song M, Yuan Y, Ding K, ANCHOR Study Group

Open source

DOI: 10.1038/s41392-026-02938-4
Published: 2026 Sep 1
Container: Signal transduction and targeted therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41392-026-02938-4,
  title = {First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.},
  author = {Liu Y and Zhang Y and Lin R and Chen X and Wang J and Yang M and Qu X and Li Y and Li J and Zhang W and Mao Y and Wang Z and Liu Z and Lei J and Xu Y and Jiang Y and Pan Z and Zhu L and Liu C and Song M and Yuan Y and Ding K and ANCHOR Study Group},
  year = {2026},
  journal = {Signal transduction and targeted therapy},
  doi = {10.1038/s41392-026-02938-4},
  url = {https://doi.org/10.1038/s41392-026-02938-4}
}

RIS

TY  - JOUR
TI  - First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.
AU  - Liu Y
AU  - Zhang Y
AU  - Lin R
AU  - Chen X
AU  - Wang J
AU  - Yang M
AU  - Qu X
AU  - Li Y
AU  - Li J
AU  - Zhang W
AU  - Mao Y
AU  - Wang Z
AU  - Liu Z
AU  - Lei J
AU  - Xu Y
AU  - Jiang Y
AU  - Pan Z
AU  - Zhu L
AU  - Liu C
AU  - Song M
AU  - Yuan Y
AU  - Ding K
AU  - ANCHOR Study Group
PY  - 2026
JO  - Signal transduction and targeted therapy
DO  - 10.1038/s41392-026-02938-4
UR  - https://doi.org/10.1038/s41392-026-02938-4
ER  -

APA

Y, L., Y, Z., R, L., X, C., J, W., M, Y., X, Q., Y, L., J, L., W, Z., Y, M., Z, W., Z, L., J, L., Y, X., Y, J., Z, P., L, Z., C, L., M, S., Y, Y., K, D., & Group, A. S. (2026). First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial.. Signal transduction and targeted therapy. https://doi.org/10.1038/s41392-026-02938-4

Source records

pubmed · retrieved 2026-09-26T13:16:09.701Z